Figure 1.

Study design: 124‐week analysis of efficacy, impact on quality of life and safety of adalimumab (ADA) in Japanese patients with moderate to severe hidradenitis suppurativa (HS). Patients who switched to the 80 mg every other week dosing regimen had visits at week 0x, week 4x and week 12x, and then visits every 12 weeks until the study end. AN, total abscess and inflammatory nodule. Adapted from Morita et al. ¹⁶